Literature DB >> 27875302

Proteasomal Degradation of the EWS-FLI1 Fusion Protein Is Regulated by a Single Lysine Residue.

Maria E Gierisch1, Franziska Pfistner1, Laura A Lopez-Garcia1, Lena Harder1, Beat W Schäfer2, Felix K Niggli1.   

Abstract

E-26 transformation-specific (ETS) proteins are transcription factors directing gene expression through their conserved DNA binding domain. They are implicated as truncated forms or interchromosomal rearrangements in a variety of tumors including Ewing sarcoma, a pediatric tumor of the bone. Tumor cells express the chimeric oncoprotein EWS-FLI1 from a specific t(22;11)(q24;12) translocation. EWS-FLI1 harbors a strong transactivation domain from EWSR1 and the DNA-binding ETS domain of FLI1 in the C-terminal part of the protein. Although Ewing cells are crucially dependent on continuous expression of EWS-FLI1, its regulation of turnover has not been characterized in detail. Here, we identify the EWS-FLI1 protein as a substrate of the ubiquitin-proteasome system with a characteristic polyubiquitination pattern. Using a global protein stability approach, we determined the half-life of EWS-FLI1 to lie between 2 and 4 h, whereas full-length EWSR1 and FLI1 were more stable. By mass spectrometry, we identified two ubiquitin acceptor lysine residues of which only mutation of Lys-380 in the ETS domain of the FLI1 part abolished EWS-FLI1 ubiquitination and stabilized the protein posttranslationally. Expression of this highly stable mutant protein in Ewing cells while simultaneously depleting the endogenous wild type protein differentially modulates two subgroups of target genes to be either EWS-FLI1 protein-dependent or turnover-dependent. The majority of target genes are in an unaltered state and cannot be further activated. Our study provides novel insights into EWS-FLI1 turnover, a critical pathway in Ewing sarcoma pathogenesis, and lays new ground to develop novel therapeutic strategies in Ewing sarcoma.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  ETS transcription factor family; cancer biology; proteasome; transcription target gene; ubiquitin

Mesh:

Substances:

Year:  2016        PMID: 27875302      PMCID: PMC5207197          DOI: 10.1074/jbc.M116.752063

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  61 in total

1.  Inhibition of EWS-FLI-1 fusion protein with antisense oligodeoxynucleotides.

Authors:  J A Toretsky; Y Connell; L Neckers; N K Bhat
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

2.  Interaction of murine ets-1 with GGA-binding sites establishes the ETS domain as a new DNA-binding motif.

Authors:  J A Nye; J M Petersen; C V Gunther; M D Jonsen; B J Graves
Journal:  Genes Dev       Date:  1992-06       Impact factor: 11.361

Review 3.  The ubiquitin system.

Authors:  A Hershko; A Ciechanover
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

4.  Solution structure of the ets domain of Fli-1 when bound to DNA.

Authors:  H Liang; X Mao; E T Olejniczak; D G Nettesheim; L Yu; R P Meadows; C B Thompson; S W Fesik
Journal:  Nat Struct Biol       Date:  1994-12

5.  Ets-1 messenger RNA expression is a novel marker of poor survival in ovarian carcinoma.

Authors:  B Davidson; R Reich; I Goldberg; W H Gotlieb; J Kopolovic; A Berner; G Ben-Baruch; M Bryne; J M Nesland
Journal:  Clin Cancer Res       Date:  2001-03       Impact factor: 12.531

Review 6.  Translocation-related sarcomas.

Authors:  Fredrik Mertens; Cristina R Antonescu; Peter Hohenberger; Marc Ladanyi; Piergiorgio Modena; Maurizio D'Incalci; Paolo G Casali; Massimo Aglietta; Thor Alvegård
Journal:  Semin Oncol       Date:  2009-08       Impact factor: 4.929

7.  EWS/FLI and its downstream target NR0B1 interact directly to modulate transcription and oncogenesis in Ewing's sarcoma.

Authors:  Michelle Kinsey; Richard Smith; Anita K Iyer; Edward R B McCabe; Stephen L Lessnick
Journal:  Cancer Res       Date:  2009-11-17       Impact factor: 12.701

Review 8.  The impact of translocations and gene fusions on cancer causation.

Authors:  Felix Mitelman; Bertil Johansson; Fredrik Mertens
Journal:  Nat Rev Cancer       Date:  2007-03-15       Impact factor: 60.716

9.  Truncated ERG Oncoproteins from TMPRSS2-ERG Fusions Are Resistant to SPOP-Mediated Proteasome Degradation.

Authors:  Jian An; Shancheng Ren; Stephen J Murphy; Sumiya Dalangood; Cunjie Chang; Xiaodong Pang; Yangyan Cui; Liguo Wang; Yunqian Pan; Xiaowei Zhang; Yasheng Zhu; Chenji Wang; Geoffrey C Halling; Liang Cheng; William R Sukov; R Jeffrey Karnes; George Vasmatzis; Qing Zhang; Jun Zhang; John C Cheville; Jun Yan; Yinghao Sun; Haojie Huang
Journal:  Mol Cell       Date:  2015-09-03       Impact factor: 17.970

10.  SPOP Promotes Ubiquitination and Degradation of the ERG Oncoprotein to Suppress Prostate Cancer Progression.

Authors:  Wenjian Gan; Xiangpeng Dai; Andrea Lunardi; Zhen Li; Hiroyuki Inuzuka; Pengda Liu; Shoreh Varmeh; Jinfang Zhang; Liang Cheng; Yin Sun; John M Asara; Andrew H Beck; Jiaoti Huang; Pier Paolo Pandolfi; Wenyi Wei
Journal:  Mol Cell       Date:  2015-09-03       Impact factor: 17.970

View more
  12 in total

1.  The E3 ubiquitin ligase HECW1 targets thyroid transcription factor 1 (TTF1/NKX2.1) for its degradation in the ubiquitin-proteasome system.

Authors:  Jia Liu; Su Dong; Lian Li; Heather Wang; Jing Zhao; Yutong Zhao
Journal:  Cell Signal       Date:  2019-03-05       Impact factor: 4.315

2.  ERG activity is regulated by endothelial FAK coupling with TRIM25/USP9x in vascular patterning.

Authors:  Gabriela D'Amico; Isabelle Fernandez; Jesús Gómez-Escudero; Hyojin Kim; Eleni Maniati; Muhammad Syahmi Azman; Faraz K Mardakheh; Bryan Serrels; Alan Serrels; Maddy Parsons; Anthony Squire; Graeme M Birdsey; Anna M Randi; Alfonso Bolado-Carrancio; Rathi Gangeswaran; Louise E Reynolds; Natalia Bodrug; Yaohe Wang; Jun Wang; Pascal Meier; Kairbaan M Hodivala-Dilke
Journal:  Development       Date:  2022-07-12       Impact factor: 6.862

3.  Targeted inhibition of histone deacetylase leads to suppression of Ewing sarcoma tumor growth through an unappreciated EWS-FLI1/HDAC3/HSP90 signaling axis.

Authors:  Yan Ma; Michael Baltezor; Lian Rajewski; Jennifer Crow; Glenson Samuel; Vincent S Staggs; Katherine M Chastain; Jeffrey A Toretsky; Scott J Weir; Andrew K Godwin
Journal:  J Mol Med (Berl)       Date:  2019-04-25       Impact factor: 5.606

4.  Boosting mTOR-dependent autophagy via upstream TLR4-MyD88-MAPK signalling and downstream NF-κB pathway quenches intestinal inflammation and oxidative stress injury.

Authors:  Mingxia Zhou; Weimin Xu; Jiazheng Wang; Junkai Yan; Yingying Shi; Cong Zhang; Wensong Ge; Jin Wu; Peng Du; Yingwei Chen
Journal:  EBioMedicine       Date:  2018-08-29       Impact factor: 8.143

5.  One oncogene, several vulnerabilities: EWS/FLI targeted therapies for Ewing sarcoma.

Authors:  Guillermo Flores; Patrick J Grohar
Journal:  J Bone Oncol       Date:  2021-12-01       Impact factor: 4.072

Review 6.  Ubiquitin-Mediated Control of ETS Transcription Factors: Roles in Cancer and Development.

Authors:  Charles Ducker; Peter E Shaw
Journal:  Int J Mol Sci       Date:  2021-05-12       Impact factor: 5.923

7.  USP19 deubiquitinates EWS-FLI1 to regulate Ewing sarcoma growth.

Authors:  Maria E Gierisch; Gloria Pedot; Franziska Walser; Laura A Lopez-Garcia; Patricia Jaaks; Felix K Niggli; Beat W Schäfer
Journal:  Sci Rep       Date:  2019-01-30       Impact factor: 4.379

Review 8.  Targeting the undruggable: exploiting neomorphic features of fusion oncoproteins in childhood sarcomas for innovative therapies.

Authors:  Maximilian M L Knott; Tilman L B Hölting; Shunya Ohmura; Thomas Kirchner; Florencia Cidre-Aranaz; Thomas G P Grünewald
Journal:  Cancer Metastasis Rev       Date:  2019-12       Impact factor: 9.264

9.  SPOP and OTUD7A Control EWS-FLI1 Protein Stability to Govern Ewing Sarcoma Growth.

Authors:  Siyuan Su; Jianfeng Chen; Yao Jiang; Ying Wang; Tamara Vital; Jiaming Zhang; Christian Laggner; Kong T Nguyen; Zhichuan Zhu; Alex W Prevatte; Natalie K Barker; Laura E Herring; Ian J Davis; Pengda Liu
Journal:  Adv Sci (Weinh)       Date:  2021-06-01       Impact factor: 16.806

10.  TRIM8 modulates the EWS/FLI oncoprotein to promote survival in Ewing sarcoma.

Authors:  Bo Kyung A Seong; Neekesh V Dharia; Shan Lin; Katherine A Donovan; Shasha Chong; Amanda Robichaud; Amy Conway; Amanda Hamze; Linda Ross; Gabriela Alexe; Biniam Adane; Behnam Nabet; Fleur M Ferguson; Björn Stolte; Emily Jue Wang; Jialin Sun; Xavier Darzacq; Federica Piccioni; Nathanael S Gray; Eric S Fischer; Kimberly Stegmaier
Journal:  Cancer Cell       Date:  2021-07-29       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.